Publicaciones
-
Valladares-Ayerbes, M; Safont, MJ; Gonzalez-Flores, E; Garcia-Alfonso, P; Aguilar, EA; Munoz, AML; Nogueras, LC; Ferrer, EF; Salas, NR; Aparicio, J; Llanos, M; Trujillo, OAC; Caceres, PP; Cruz-Hernandez, JJ; Fernandez, MS; Salvia, AS; Garcia-Carbonero, R; Sureda, BM; Conesa, MAV; Vila, AL
Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
ANNALS OF ONCOLOGY 32 560-560. .
-
Parisi E; Sorolla A; Montal R; González-Resina R; Novell A; Salud A; Sorolla MA
Prognostic Factors Involved in the Epithelial-Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis.
Cancers 12 1-28. .
-
Aranda E; Viéitez JM; Gómez-España A; Gil Calle S; Salud-Salvia A; Graña B; Garcia-Alfonso P; Rivera F; Quintero-Aldana GA; Reina-Zoilo JJ; González-Flores E; Salgado Fernández M; Guillén-Ponce C; Garcia-Carbonero R; Safont MJ; La Casta Munoa A; García-Paredes B; López López R; Sastre J; Díaz-Rubio E
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and =3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
ESMO Open 5 -. .
-
Camps Herrero, C; Batista, N; Diaz Fernandez, N; Escobar Alvarez, Y; Gonzalo Gomez, A; Isla Casado, D; Salud, A; Terrasa Pons, J; Guillem Porta, V
Breakthrough cancer pain: review and calls to action to improve its management
CLINICAL & TRANSLATIONAL ONCOLOGY 22 1216-1226. .
-
Porcel, JM; Torres, M; Pardina, M; Civit, C; Salud, A; Bielsa, S
Predictors of Indwelling Pleural Catheter Removal and Infection A Single-center Experience With 336 Procedures
JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY 27 86-94. .
-
Rivera, F; Romero, C; Jimenez-Fonseca, P; Izquierdo-Manuel, M; Salud, A; Martínez E; Jorge, M; Arrazubi, V; Méndez JC; García-Alfonso P; Reboredo, M; Barriuso, J; Mu?oz-Unceta, N; Jimeno, R; López C
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial (vol 83, pg 1175, 2019)
CANCER CHEMOTHERAPY AND PHARMACOLOGY 84 1365-1365. .
-
García-Albéniz X; Alonso, V; Escudero, P; Méndez M; Gallego, J; Rodríguez JR; Salud, A; Fernández-Plana J; Manzano, H; Zanui, M; Falc?, E; Feliu, J; Gil, M; Fernández-Martos C; Bohn, U; Alonso, C; Calderero, V; Rojo, F; Cuatrecasas, M; Maurel, J
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
Oncologist 24 1115-1122. .
-
Fernandez-Martos, C; Pericay, C; Losa, F; Garcia-Carbonero, R; Layos, L; Rodriguez-Salas, N; Martin-Richard, M; Alonso-Orduna, V; Vera, R; Gallego, J; Capdevila, J; Salud, A; Nogue, M; Maurel, J; Guash, I; Montagut, C; Lopez, C; Macias, I; Jain, RK; Garcia-Albeniz, X
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma The GEMCAD 1402 Randomized Clinical Trial
JAMA Oncology 5 1566-1573. .
-
Porcel, JM; Esquerda, A; Bielsa, S; Novell, A; Sorolla, MA; Gatius, S; Zamora, C; Vidal, S; Salud, A
Epithelial cell adhesion molecule (EpCAM) from pleural fluid cell lysates is a highly accurate diagnostic biomarker of adenocarcinomatous effusions
RESPIROLOGY 24 799-804. .
-
Carrato, A; Benavides, M; Massuti, B; Ferreiro-Monteagudo, R; García Alfonso P; Falco, E; Reboredo, M; Cano, T; Gallego, J; Vieitez, JM; Layos, L; Salud, A; Polo, E; Dotor, E; Duran-Ogalla, G; Rodriguez-Garrote, M; Calvo, A; Grande, E; Aranda, E
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Bmc Cancer 19 533-533. .
-
Rivera, F; Romero, C; Jimenez-Fonseca, P; Izquierdo-Manuel, M; Salud, A; Martinez, E; Jorge, M; Arrazubi, V; Mendez, JC; Garcia-Alfonso, P; Reboredo, M; Barriuso, J; Muñoz-Unceta N; Jimeno, R; Lopez, C
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
CANCER CHEMOTHERAPY AND PHARMACOLOGY 83 1175-1181. .
-
Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Salazar R; Aranda E
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial
ANNALS OF ONCOLOGY 30 796-803. .
Proyectos
- Ajuts per a la contractació de personal investigador novell (FI)
- Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
- Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
- UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante
